Privium Fund Management (UK)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Privium Fund Management (UK)’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8,800	Closed	-$798K	–	186
2024 Q1	$798K	Sell	8,800 -8,800	-50%	-$817K	0.4%	46
2023 Q4	$1.59M	Buy	+17,600	New	+$1.31M	1.08%	29
2023 Q3	–	Sell	-18,790	Closed	-$1.55M	–	89
2023 Q2	$1.55M	Hold	18,790	–	–	1.22%	27
2023 Q1	$1.4M	Hold	18,790	–	–	1.11%	31
2022 Q4	$1.55M	Buy	+18,790	New	+$1.52M	1.17%	29
2021 Q3	–	Sell	-5,000	Closed	-$677K	–	75
2021 Q2	$677K	Buy	+5,000	New	+$657K	0.47%	39

Other funds holding XBI

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Privium Fund Management (UK)'s XBI Position: Q2 2024 in Review

Privium Fund Management (UK) sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 8,800 shares — an estimated $798K sold.

Privium Fund Management (UK) first reported a position in XBI in Q2 2021 and held it in 6 quarters. The position peaked at $1.59M in Q4 2023. 761 funds tracked by Wall St. Rank hold XBI as of Q2 2024.

Privium Fund Management (UK) reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
Privium Fund Management (UK) sold 8,800 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $798K.
Privium Fund Management (UK) first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and held it in 6 quarters.
Privium Fund Management (UK)'s State Street SPDR S&P Biotech ETF position peaked at $1.59M in Q4 2023.
761 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.

Based on Privium Fund Management (UK)'s 13F filing for Q2 2024, filed 2 Aug 2024.